About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
We are dedicated to investigate transfusional activity, the alteration of erythrocytes during the conservation period and extracorporeal photoapheresis. We work on the molecular and serological characterization of blood group variants. In non-invasive fetal genotyping strategies due to blood group incompatibilities. We develop iPSC lines and produce in vitro erythrocytes with rare phenotypes. We deepen in the knowledge of epidemiology and the detection of infectious agents relevant for safety of the products supplied by the Blood and Tissue Bank.
We investigate in clinical immunology and develop our own HLA and KIR typing protocols. We develop and incorporate new therapeutic applications in cell therapy including hematopoietic transplantation, cellular immunology and regenerative medicine. We investigate the molecular mechanisms and genotype-phenotype correlation of coagulopathies, haemorrhagic diathesis and other associated congenital pathologies. We develop tools based on the new technologies of parallel massive sequencing with application to the molecular study, genetic counselling and prenatal diagnosis.
PMID: 38158197 Journal: THROMBOSIS AND HAEMOSTASIS Year: 2023 Reference: Thromb Haemost. 2023 Dec 29. doi: 10.1055/s-0043-1778070. Impact factor: Publication type: Paper in international publication Authors: Bandini, Perla; Berrueco, Ruben; Borras, Nina; Comes, Natalia; Corrales, Irene; Gassiot, Susanna; Hobeich, Carlos; Martin-Fernandez, Laura; Ramirez, Lorena; Sarrate, Edurne et al. DOI: 10.1055/s-0043-1778070
